


PHARMACEUTICAL 2022

Blueprint Medicines Corp Rank 306 of 475









PHARMACEUTICAL 2022



Blueprint Medicines Corp Rank 306 of 475

The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 213% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 142% points.

The company's Economic Capital Ratio, given in the ranking table, is -201%, being 75% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	554,025
Cost of Goods Sold	17,934
Intangible Assets	0
Liabilities, Current	149,765
Liabilities, Non-Current	131,725
Other Assets	667,500
Other Compr. Net Income	1,081
Other Expenses	10,802
Other Liabilities	0
Other Net Income	897
Property and Equipment	30,700
Research and Development	601,033
Revenues	180,080
Selling, General and Administrative Expense	195,293

Output Variable	Value in 1000 USD
Assets	1,252,225
Liabilities	281,490
Expenses	825,062
Stockholders Equity	970,735
Net Income	-644,085
Comprehensive Net Income	-643,544
Economic Capital Ratio	-201%

